NCT07014007View on ClinicalTrials.gov

Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks

NANot yet recruitingINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

September 29, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Atopic Dermatitis

Interventions

DEVICE

RV4421B- EV0407

Medical device. Product application on studied areas, 5 to 15 minutes after corticosteroids application, if applicable. The maximum duration of application of medical device is 87 days.

All Listed Sponsors

lead

Pierre Fabre Dermo Cosmetique

INDUSTRY

NCT07014007 - Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks | Biotech Hunter | Biotech Hunter